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Results The EGFR-targeted nanoparticle EGFR–BSA–
PCL and the non-targeted nanoparticle BSA–PCL were con-
structed; the effective diameters were approximately 100 nm. 
The results from flow cytometry and confocal microscopy 
revealed significant uptake of EGFR–BSA–PCL in EGFR-
overexpressing tumor cells. Compared with EGFR–BSA–
PCL, BSA–PCL could also bind to cells, but tumor cell 
retention was minimal and weak. In MTT assays, the EGFR-
targeted radioactive nanoparticle 131I–EGFR–BSA–PCL 
showed greater cytotoxicity and targeted cell killing than the 
non-targeted nanoparticle 131I–BSA–PCL. The radioiodine 
uptake of both 131I-labeled nanoparticles, 131I–EGFR–BSA–
PCL and 131I–BSA–PCL, was rapid and reached maximal 
levels 4 h after incubation, but the 131I uptake of 131I–EGFR–
BSA–PCL was higher than that of 131I–BSA–PCL. On day 
15, the average tumor volumes of the 131I–EGFR–BSA–PCL 
and 131I–BSA–PCL groups showed a slow growth relation-
ship compared with that of the control group.
Conclusion The EGFR-targeted nanoparticle EGFR–
BSA–PCL demonstrated superior cellular binding and 
uptake compared with those of the control BSA–PCL. The 
EGFR-targeted radioactive nanoparticle 131I–EGFR–BSA–
PCL exhibited favorable intracellular retention of 131I. 
Radionuclide therapy using 131I–EGFR–BSA–PCL, which 
showed excellent targeted cell killing, suppressed cancer 
cell growth caused by EGFR overexpression.
Keywords Epidermal growth factor receptor · 
Nanoparticles · 131I · Radioiodine therapy · Tumor-targeting
Introduction
Nanoparticles, including liposomes and other nanoscale 
constructs, can be used to combine a therapeutic agent 
Abstract 
Introduction Anti-epidermal growth factor receptor 
(EGFR)-targeted nanoparticles can be used to deliver a 
therapeutic and imaging agent to EGFR-overexpressing 
tumor cells. 131I-labeled anti-EGFR nanoparticles derived 
from cetuximab were used as a tumor-targeting vehicle in 
radionuclide therapy.
Methods This paper describes the construction of the 
anti-EGFR nanoparticle EGFR–BSA–PCL. This nanopar-
ticle was characterized for EGFR-targeted binding and cel-
lular uptake in EGFR-overexpressing cancer cells by using 
flow cytometry and confocal microscopy. Anti-EGFR and 
non-targeted nanoparticles were labeled with 131I using the 
chloramine-T method. Analyses of cytotoxicity and tar-
geted cell killing with 131I were performed using the MTT 
assay. The time-dependent cellular uptake of 131I-labeled 
anti-EGFR nanoparticles proved the slow-release effects 
of nanoparticles. A radioiodine therapy study was also per-
formed in mice.
Wei Li and Zhongyun Liu have contributed equally to this work.
 * Jian Tan 
 tanpost@163.com
1 Department of Nuclear Medicine, Tianjin Medical University 
General Hospital, Anshan Road 154, Heping District, 
Tianjin 300052, People’s Republic of China
2 Yantai Institute of Coastal Zone Research, Chinese Academy 
of Sciences, Yantai 264003, Shandong, People’s Republic 
of China
3 Institute of Nanobiotechnology, School of Materials Science 
and Engineering, Tianjin Key Laboratory of Composites 
and Functional Materials, Tianjin University, Tianjin 300072, 
People’s Republic of China
620 J Cancer Res Clin Oncol (2016) 142:619–632
1 3
with an imaging agent, thereby allowing direct monitor-
ing of drug delivery to tumors. The size of fenestrations 
in the tumor endothelium allows nanoparticles to pass 
from the circulation into the tumor interstitium where they 
can access cancer cells. Furthermore, molecules may also 
become trapped in this interstitium, which is a phenom-
enon generally referred to as the enhanced permeability 
and retention effect (Saha et al. 2010). Several types of 
nanoparticles, such as metal-, polymer-, and lipid-based 
nanoparticles, have been developed to deliver therapeutic 
agents, including chemotherapeutic agents, radionuclides, 
photosensitizers, and siRNA. Targeting ligands/moieties, 
such as peptides, antibodies, or antibody fragments, can be 
attached to nanoparticles to improve therapeutic efficacy 
(Hussain et al. 2013). In an attempt to increase specific-
ity, liposomes, which are spherical vesicles formed by lipid 
bilayers, have been conjugated to monoclonal antibodies 
or antibody fragments for specific delivery to target cells. 
Studies have shown that antibody-conjugated liposomes 
caused significant tumor cytotoxicity and growth inhibi-
tion compared with non-targeted liposomes, making them a 
promising tool for future treatment in oncology (Pastorino 
et al. 2003).
Epidermal growth factor receptor (EGFR) is one of the 
four members of the epidermal growth factor receptor fam-
ily. It plays an important role in the proliferation, apoptosis, 
dedifferentiation, angiogenesis, invasion, and metastasis 
of tumor cells. As reported by some studies, 40–80 % of 
non-small cell lung cancers (NSCLC) (Chen et al. 2012), 
20–25 % of breast cancers (Capelan et al. 2013), 35–40 % 
of colorectal cancers (Normanno et al. 2009), and 80–90 % 
of head and neck squamous cell carcinomas (HNSCC) 
(Ang et al. 2002) showed EGFR overexpression. Molecular 
imaging and targeted therapy against EGFR are significant 
areas in cancer research, and several monoclonal antibod-
ies against EGFR are available. The most advanced clini-
cal member of this drug class is cetuximab (IMC-C225 or 
Erbitux; ImClone Systems Inc., NY, USA/Merck KGaA, 
Darmstadt, Germany), which competitively inhibits bind-
ing to both EGFR and EGFRvIII; cetuximab is the first 
FDA-approved EGFR-specific mAb for the treatment of 
patients with EGFR-expressing metastatic colorectal and 
head/neck cancers (Giaccone 2005). Anti-EGFR immunoli-
posomes have already been produced (Mamot et al. 2003).
Radioiodine therapy for differentiated thyroid carci-
noma has been used for numerous years. Radioiodine kills 
not only sodium iodide symporter-expressing cells but 
also adjacent tumor cells because of the cross-fire effect of 
radiation therapy. In this paper, we describe the construc-
tion of 131I-labeled anti-EGFR nanoparticles derived from 
cetuximab as a tumor-targeting vehicle for radionuclide 
therapy. These nanoparticles were characterized for cellu-
lar uptake, cytotoxicity, targeted cell killing with 131I, and 
time-dependent cellular uptake of 131I in breast cancer, 
colorectal cancer, NSCLC, and HNSCC cells in vitro; we 
also performed a radioiodine therapy study in NCI-H1972 




Reagents were obtained from the following sources: Dul-
becco’s modified Eagle’s medium (DMEM) (Gibco), 
Roswell Park Memorial Institute (RPMI) 1640 medium 
(Gibco), Minimum Essential Medium Eagles with Ear-
le’s Balanced Salts (MEM-EBSS) (Gibco), fetal bovine 
serum (FBS) (Gibco), rabbit polyclonal antihuman epi-
dermal growth factor receptor antibody (Abcam, ab2430), 
and 5 mg/mL monoclonal antibody (MERCK Inc., C225, 
cetuximab).
Cell lines
The NSCLC cell lines NCI-H292 and NCI-H1975; breast 
cancer cell lines MDA-MB-231, MDA-MB-453, and 
MDA-MB-468; colorectal cancer cell line LS180; and 
squamous cell carcinoma cell line A431 were purchased 
from Cell Resource Center, Institute of Basic Medical 
Sciences, Chinese Academy of Medical Sciences/Peking 
Union Medical College (Beijing, China); EGFR was over-
expressed in all of these cell lines (Mamot et al. 2003, 
2006; Nagaria et al. 2013; Zhou et al. 2012). The cell lines 
MDA-MB-231, MDA-MB-453, MDA-MB-468, and A431 
were cultured in DMEM supplemented with 10 % FBS and 
1 % penicillin/streptomycin. The cell lines NCI-H292 and 
NCI-H1975 were cultured in RPMI 1640 medium supple-
mented with 10 % FBS and 1 % penicillin/streptomycin. 
The cell line LS180 was cultured in MEM-EBSS medium 
supplemented with 10 % FBS and 1 % penicillin/strepto-
mycin. The cell cultures were stored in a humidified atmos-
phere containing 5 % CO2 buffered with ambient air at 
37 °C.
Preparation, conjugation, and characterization 
of nanoparticles (Liu et al. 2014)
The amphiphilic BSA–PCL conjugate was synthesized as 
previously described (Liu et al. 2014), and the nanosized 
self-assembled amphiphilic BSA–PCL conjugate was 
obtained via the emulsion–solvent evaporation method (Du 
et al. 2013). Briefly, 4 mg of BSA–PCL conjugate was dis-
solved in 4 mL of phosphate buffer (PB, 0.1 M, pH 7.4) at 
room temperature and activated with N-(3-dimethyl amino 
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propyl)-3-2 ethyl carbon imine hydrochloride (EDC) and 
N-hydroxy succinimide (NHS) for 15 min, to which 5 mg/
mL cetuximab antibodies were added (100 μg cetuximab 
antibodies per 1 mg BSA–PCL) at 4 °C overnight. The 
obtained PB solutions of the self-assemblies of the BSA–
PCL conjugate and the cetuximab-decorated BSA–PCL 
conjugate EGFR–BSA–PCL were stored at 4 °C. The 
EGFR–BSA–PCL and BSA–PCL conjugates were syn-
thesized by Liu Zhongyun, Ph.D., and Professor Chang Jin 
from TianJin University, Department of Polymer Materials 
Science and Engineering (Liu et al. 2014). Nanoparticles 
were dissolved in 10 % Triton X-100 for measurement of 
BSA and cetuximab antibody content by high-performance 
liquid chromatography (HPLC) (Chen et al. 2015). Meas-
urement of the amount of antibody per nanoparticle was 
performed by the ratio of their surface areas; the BSA and 
EGFR protein qualification were performed by high-per-
formance liquid chromatography (HPLC), and the detailed 
description is provided by in Kao et al. (2013) and Cho 
et al. (2010).
Nanoparticle targeting in EGFR overexpression cell 
lines (Cho et al. 2010; Du et al. 2013; Kao et al. 2013)
The cellular binding and uptake of two different nanoparti-
cles, EGFR–BSA–PCL and BSA–PCL, were evaluated by 
confocal microscopy and flow cytometry in seven EGFR-
overexpressing cell lines (MDA-MB-231, MDA-MB-453, 
MDA-MB-468, NCI-H292, NCI-H1975, LS180, and 
A431). The nanoparticles were added at a concentration of 
1 mg/106 cells and incubated for 4 h at 37 °C. After incu-
bation, the cells were washed three times with PBS, fixed 
with 4 % paraformaldehyde, and analyzed by confocal 
microscopy (laser scanning confocal microscope; Olympus 
FV1000, Japan).
Flow cytometry was used to quantify the targeting poten-
tial of the nanoparticles. Flow cytometry was performed 
using a FACScan Cytometer (BD FACSCalibur; BD Bio-
sciences, USA) by counting 30,000 events, and the data 
were analyzed using FlowJo software. The experiments 
were performed as follows: nanoparticles were added at 
a concentration of 1 mg/106 cells and incubated for 4 h at 
37 °C. After incubation, 5 × 106 cells were washed twice 
with 500 μL of PBS buffer by centrifugation (2000 rpm 
for 10 min), and a 250-μL cell suspension was obtained. 
Another 250 μL of 4 % paraformaldehyde was then added 
and analyzed by flow cytometry.
Direct labeling (Nordberg et al. 2007)
EGFR–BSA–PCL and BSA–PCL were labeled with 131I 
(Beijing atomic Hi-tech Co., Ltd.) using the chloramine-
T method. Approximately 100 µg of EGFR–BSA–PCL or 
BSA–PCL was diluted in PB to a total volume of 100 μL, 
and ~74 MBq 131I was added. Chloramine-T (100 μL; 
5 mg/mL in PB) was added. After 60 s of shaking and 
incubation, the reaction was stopped by adding 100 μL of 
sodium metabisulfite (5 mg/mL in PB). To separate labeled 
EGFR–BSA–PCL and BSA–PCL from low molecular 
weight compounds, a centrifuge tube (Amicon® Pro Puri-
fication System, Merck Millipore) was used. The specific 
radioactivity was approximately 370–690 MBq/mg for 
131I–EGFR–BSA–PCL and 131I–BSA–PCL. The labeling 
rate of 131I was approximately 50–85 %.
Competitive effect study in vitro (Du et al. 2013)
To further investigate the competitive effect of EGFR on 
the uptake of the nanoparticles, tumor cells were seeded 
in 24-well plates overnight and were incubated with 131I–
EGFR–BSA–PCL and 131I–BSA–PCL for 1 h; radioactivity 
was measured using a γ counter (LKB gamma 1261; LKB 
Instruments). Next, 500 μL rhEGF (0.2 ng/mL, Promega, 
USA) was added to these cells for 1 h, and then tumor cells 
were incubated with 131I–EGFR–BSA–PCL for another 
1 h. After incubation, cells were washed three times with 
PBS before radioactivity was measured.
Western blot analysis
For Western blot analysis, the PS 2A200 electrophore-
sis system (Amersham Biosciences, USA) was used. 
Membranes were incubated with EGFR (dilution 1:1000, 
sc-120, Abcam, USA) or β-actin (dilution 1:1000, TA-09, 
Novus Biologicals, USA) antibodies for 2 h at room tem-
perature. The membranes were then incubated with sec-
ondary antibodies at room temperature for another 1 h 
and covered with Pierce ECL Western Blotting Substrate 
(Thermo Fisher Scientific, USA) at room temperature for 
1 min and exposed to Fuji X-ray film in the darkroom. Pre-
stained protein molecular weight standards (Spectra Mul-
ticolor Broad Range Protein Ladder, SM1841, Fermentas, 
Germany) were run in the same gels for molecular weight 
comparison and estimation of transfer efficiency.
Cell killing with 131I and MTT assay (Chung et al. 2011)
To examine the effects of 131I–EGFR–BSA–PCL and 
131I–BSA–PCL on cell growth, tumor cells were seeded 
in 96-well plates at 1 × 104 cells per well overnight and 
were incubated with 131I–EGFR–BSA–PCL or 131I–BSA–
PCL under different concentration doses for 4 h. All of the 
nanoparticles were then wiped off, and the cells were incu-
bated for another 24 h. To examine whether radionuclide 
nanoparticles can kill tumor cells, the cells were exten-
sively washed twice with PBS, and 20 μL of MTT reagent 
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(5.0 mg/mL) [3-(4, 5 dimethylthiazol-2-yl)-2, 5-diphenyl 
tetrazolium bromide; Sigma] was added to each well for 
4 h. The amount of formazan blue compound indicates the 
number of living cells and was determined using a spectro-
photometer (BioTek, ELX800, USA) at λ = 492 nm.
Time‑dependent cellular uptake of 131I–EGFR–BSA–
PCL and 131I–BSA–PCL (Nordberg et al. 2007)
To measure the time-dependent cellular uptake of 
131I-labeled nanoparticles, 1 × 105 cells per well were 
seeded in 96-well plates and cultured with 3.7 MBq/mL 
131I–EGFR–BSA–PCL, 131I–BSA–PCL, or 131I. The cells 
were washed, lysed with 0.3 M sodium hydroxide, and 
counted every 2 h for 4 h, every 4 h until 12 h, and then 
every 6 h until 24 h. Radioactivity was measured using a γ 
counter (LKB gamma 1261; LKB Instruments). All of the 
experiments were performed in triplicate. 131I could not be 
retained in non-thyroid cells, so these cells comprised the 
control group.
Animal model
Experimental animals were purchased from the Beijing 
Experimental Animal Center of Peking Union Medical, 
China. The generation of subcutaneous tumors was per-
formed as follows: a 5 × 106 NCI-H1972 tumor cell sus-
pension in 50 µL of DMEM was subcutaneously injected 
into the right shoulder of 4-week-old BALB/c female nude 
mice weighing 19–21 g. Mice were kept under specific 
pathogen-free conditions at the Laboratory Animal Center, 
Tianjin Medical University, China. The animal experiment 
guidelines were followed according to the regulations of 
Swiss veterinary law. The results were similar to those of 
the in vitro clonogenic assay in MDA-MB-231, MDA-
MB-453, MDA-MB-468, NCI-H292, NCI-H1975, LS180, 
and A431 EGFR-overexpressing tumor cells. Therefore, 
NCI-H1972 cells were selected for animal testing. For the 
therapeutic experiments, all 20 mice were divided into four 
groups in terms of the 131I-labeled EGFR-targeted nanopar-
ticle 131I–EGFR–BSA–PCL, the 131I-labeled non-targeted 
nanoparticle 131I–BSA–PCL, the EGFR-targeted nanopar-
ticle EGFR–BSA–PCL, and the non-targeted nanoparticle 
BSA–PCL.
Tissue distribution of 131I, 131I–EGFR–BSA–PCL, 
and 131I–BSA–PCL
The mice bearing human cancer were used for the biodis-
tribution study at day 21 after tumor inoculation. The mice 
in each group were killed at 24 and 72 h post-injection 
with the respective drugs. The heart, spleen, liver, colon, 
and tumor samples were collected for weighing and for 
radioactivity measurements with a γ counter (LKB gamma 
1261; LKB Instruments). Meanwhile, the remaining spleen, 
liver, and tumor tissues were collected to study the histopa-
thology of each group. Data were expressed as each gram 
of tissue (% ID/g) (Li et al. 2004).
Radioiodine therapy study in mice
When the tumors reached a minimum size of 10 mm in 
diameter, 74 MBq (370 MBq/mL) 131I–EGFR–BSA–PCL, 
74 MBq (370 MBq/mL) 131I–BSA–PCL, 1 mg (20 mg/mL) 
EGFR–BSA–PCL, or 1 mg (20 mg/mL) BSA–PCL was 
injected into the tumor. The tumor size was monitored prior 
to the administration of radioiodine and every 3 days there-
after by measuring three diameters with a sliding caliper 
and converting the diameter to the volume using the for-
mula V = 4πabc/3. Control groups were followed to day 15 
after injection and then killed due to excessive tumor bur-
den by cervical dislocation under deep isoflurane sedation. 
The therapy groups were followed to day 35 after injection 
and were then killed.
Statistical analysis
All of the experiments were performed in triplicate unless 
otherwise indicated in vitro. Statistical analysis was con-
ducted using SPSS software version 13.0. The results are 
presented as the mean ± SD. Statistical significance was 
tested using Student’s t test or ANOVA.
Results
Size and morphology of BSA–PCL  
and EGFR–BSA–PCL
The size and morphology of the resulting BSA–PCL and 
EGFR–BSA–PCL were measured by a laser particle size 
analyzer and transmission electron microscopy (TEM). 
TEM analyses (insets of Fig. 1) of BSA–PCL and EGFR–
BSA–PCL showed that the shape of the BSA carrier was 
retained after modification. They were both well-dispersed 
nanoparticles with a spherical shape. The DLS measure-
ment showed the average diameter was approximately 
130–180 nm and the polydispersity index (PDI) was 0.164, 
in agreement with the TEM result. The mean ζ potential of 
the obtained protein-based vesicle was also measured, with 
a value of −38.70 mV. The negative surface charge that 
resulted from the BSA shell could reduce undesired protein 
adsorption and provide good protection for the vesicle dur-
ing circulation in the body. The diameter of nanoparticle 
EGFR–BSA–PCL was approximately 180 nm, the radius 
of BSA was 3.5 nm, the hydronamic radius of antibody 
623J Cancer Res Clin Oncol (2016) 142:619–632 
1 3
C225 was 1.5 nm; so, the surface area of the nanoparticle 
was 101,736 nm2, and the cross-sectional area of C225 and 
BSA were 7.1 and 38.5 nm2, respectively. According to the 
ratio of BSA and C225 measured by HPLC, the amount 
of antibody per nanoparticle was estimated to be approxi-
mately 3800 antibody molecules per nanoparticle.
Internalization of EGFR–BSA–PCL and BSA–PCL
Confocal microscopy was used to evaluate the binding of 
EGFR–BSA–PCL and BSA–PCL to target tumor cells 
with high EGFR expression. We investigated their targeting 
abilities against different cancer cells. Figure 2 shows the 
confocal images of MDA-MB-231, MDA-MB-453, MDA-
MB-468, NCI-H292, NCI-H1975, LS180, and A431 can-
cer cells incubated with EGFR–BSA–PCL and BSA–PCL. 
Immunofluorescence (Fig. 2) showed that EGFR–BSA–
PCL was significantly internalized in EGFR-overexpressed 
tumor cells and exhibited strong green fluorescence. Com-
pared with EGFR–BSA–PCL, BSA–PCL could also bind 
to cells, but tumor cell retention was minimal and the bind-
ing green fluorescence was weak. This result suggests that 
the targeting ability of nanoparticles was enhanced via 
modification with anti-EGFR antibody.
Flow cytometry of nanoparticle binding and cellular 
uptake
Fluorescence-activated cell-sorting analyses revealed results 
consistent with those observed in confocal microscopy anal-
yses, showing a significant uptake of EGFR–BSA–PCL. As 
shown in Fig. 3, rapid and efficient binding of EGFR–BSA–
PCL to EGFR-overexpressing target cell lines was demon-
strated. The binding and uptake of EGFR–BSA–PCL were 
higher than those of non-targeted nanoparticles in MDA-
MB-231, MDA-MB-453, MDA-MB-468, NCI-H292, NCI-
H1975, LS180, and A431 cell lines (p < 0.05). This finding 
implies that EGFR–BSA–PCL had a special binding effi-
ciency with tumor cells expressing EGFR.
Competitive effect study in vitro
After rhEGF was added to these cells for 1 h, radioiodide 
uptake in the rhEGF + 131I–EGFR–BSA–PCL group was 
lower than the 131I–EGFR–BSA–PCL group. The results 
showed that rhEGF bound to EGFR receptors on the sur-
faces of tumor cells, C225-mediated endocytosis of nano-
particles was restrained, the endocytosis of 131I–EGFR–
BSA–PCL was also restrained, and radioiodide uptake was 
depressed in EGFR-overexpressing tumor cells (Fig. 4).
Targeted cell killing with 131I
The EGFR expression was assayed by Western blot in 
Fig. 5. The EGFR proteins in MDA-MB-231, MDA-
MB-453, MDA-MB-468, NCI-H292, NCI-H1975, LS180, 
and A431 cancer cells were detected as major bands cor-
responding to a molecular weight at 170 kDa. The β-actin 
protein was used as a positive control and expressed in all 
cells as a major band with a molecular weight at 43 kDa.
For studies on cell killing with 131I, EGFR–BSA–PCL 
and BSA–PCL were labeled with 131I for targeted delivery 
to EGFR- or EGFRvIII-overexpressing cells. 131I–EGFR–
BSA–PCL and 131I–BSA–PCL were incubated with various 
cell lines and compared with 131I to evaluate the efficiency 
and specificity of targeted cell killing. In recent studies, a 
similar treatment with the antihuman EGFR antibody C225 
showed no cytotoxicity using the MTT assay (Mamot et al. 
2003). EGFR–BSA–PCL and BSA–PCL also showed no 
cytotoxicity using the MTT assay (Liu et al. 2014). Further-
more, nanoparticles containing C225-Fab, but lacking an 
encapsulated drug, similarly showed no cytotoxicity under 
these MTT assay conditions (Mamot et al. 2003). Thus, 131I–
EGFR–BSA–PCL and 131I–BSA–PCL were compared with 
131I to confirm EGFR-targeted cell killing using MTT assays.
Fig. 1  Diameter and TEM imaging of the self-assembly of the BSA–
PCL (a) and EGFR–BSA–PCL (b) conjugates. The effective diam-
eters of BSA–PCL (a) and EGFR–BSA–PCL (b) were approximately 
100 nm, as shown. TEM analyses of BSA–PCL and EGFR–BSA–
PCL showed that the shape of the BSA carrier was retained after 
modification
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Compared with the non-targeted nanoparticle 131I–BSA–
PCL, the EGFR-targeted radionuclide nanoparticle 131I–
EGFR–BSA–PCL showed greater cytotoxicity in vitro, 
indicating that the delivery was antibody dependent. In 
MDA-MB-231, MDA-MB-453, and MDA-MB-468 breast 
cancer cells, 131I–EGFR–BSA–PCL showed substantial 
in vitro cytotoxicity after treatment for 4 h. The IC50 val-
ues of 131I–EGFR–BSA–PCL in MDA-MB-231, MDA-
MB-453, and MDA-MB-468 breast cancer cells were 
0.31 (Fig. 6a), 0.34 (Fig. 6b), and 0.04 MBq/mL (Fig. 6c), 
respectively, whereas those of 131I–BSA–PCL were 0.71 
(Fig. 6a), 0.39 (Fig. 4b), and 0.25 MBq/mL (Fig. 6c), 
respectively. Meanwhile, the IC50 values of 131I–EGFR–
BSA–PCL in NSCLC cell lines NCI-H292 and NCI-H1972 
were 0.70 (Fig. 6e) and 0.70 MBq/mL (Fig. 6f), respec-
tively, whereas those of 131I–BSA–PCL were 1.8 (Fig. 6e) 
and 3.26 MBq/mL (Fig. 6f), respectively. The IC50 values 
of 131I–EGFR–BSA–PCL in the colorectal cancer cell line 
LS180 and squamous cell carcinoma cell line A431 were 
1.32 (Fig. 6d) and 0.03 MBq/mL (Fig. 6g), respectively, 
Fig. 2  Confocal microscopy images of cancer cells incubated 
with BSA–PCL or EGFR–BSA–PCL for 4 h. Immunofluorescence 
showed that EGFR–BSA–PCL was significantly internalized in 
EGFR-overexpressed MDA-MB-231 (a), MDA-MB-453 (b), MDA-
MB-468 (c), NCI-H292 (d), NCI-H1975 (e), LS180 (f), and A431 (g) 
tumor cells and exhibited strong green fluorescence. Compared with 
EGFR–BSA–PCL, BSA–PCL could also bind to cells, but tumor cell 
retention was minimal and the green fluorescence binding was weak
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whereas those of 131I–BSA–PCL were 12.19 (Fig. 6d) and 
0.32 MBq/mL (Fig. 6g), respectively. The survival rates of 
tumor cells not incubated with 131I that were only incubated 
with 131I were similar because non-thyroid tumor cells 
could not uptake 131I; thus, 131I retention was too short to 
kill the cells, as shown in Fig. 6.
Time‑dependent cellular uptake
To determine the iodide uptake of 131I–EGFR–BSA–PCL 
and 131I–BSA–PCL, 131I-timed activity measurements 
were obtained in MDA-MB-231, MDA-MB-453, MDA-
MB-468, LS180, NCI-H1975, NCI-H292, and A431 tumor 
Fig. 3  Binding activity of EGFR–BSA–PCL and BSA–PCL to target 
cell lines. In MDA-MB-231 (a), MDA-MB-453 (b), MDA-MB-468 
(c), LS180 (d), NCI-H1975 (e), NCI-H292 (f), and A431 (g) tumor 
cells, rapid and efficient binding of EGFR–BSA–PCL to EGFR-over-
expressing target cell lines was demonstrated (*p < 0.05, compared 
with BSA–PCL)
Fig. 4  Competitive effect study in vitro. After incubation, 131I–EGFR–BSA–PCL (a) and 131I–BSA–PCL (b) were measured using a γ counter 
(*p < 0.01, compared with rhEGF + 131I–EGFR–BSA–PCL, #p > 0.5, compared with rhEGF + 131I–BSA–PCL)
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cells in Fig. 7a–g. Radioiodide uptake in those cells was 
rapid, reaching maximal levels 4 h after incubation with 
131I–EGFR–BSA–PCL and 131I–BSA–PCL; 131I uptake of 
131I–EGFR–BSA–PCL was higher than that of 131I–BSA–
PCL as shown in Fig. 7h. Cell-associated 131I activity after 
24 h was still very high and almost 79–84 % in all seven 
cell lines because of the slow-release effect of internalized 
nanoparticles from cells.
Radioiodine therapy study in mice
Figure 8a shows the average tumor volume progression for 
the two 131I-nanoparticle therapy groups and the two cor-
responding unlabeled nanoparticle control groups. Injec-
tion on day 3 was used as the initial reference due to the 
significant tumor swelling on day 1 and day 2. On day 
35, the average tumor volumes of the 131I–EGFR–BSA–
PCL and 131I–BSA–PCL groups were 329.7 ± 135.2 and 
365.6 ± 113.8 %, respectively. On day 15, the average 
tumor volumes of the 131I–EGFR–BSA–PCL and 131I–
BSA–PCL groups were 180.9 ± 107.5 and 205.7 ± 25.2 %, 
respectively, indicating slow growth. In comparison, tumors 
in the EGFR–BSA–PCL and BSA–PCL nanoparticle con-
trol groups showed rapid growth, with tumor volumes of 
272.7 ± 138.1 and 312.2 ± 182.8 %, respectively, at day 
15.
The tissue distribution of 131I–EGFR–BSA–PCL in nude 
mice was measured by γ counts in Fig. 8b. 131I–EGFR–
BSA–PCL was markedly absorbed by tumor tissues. 
Among the non-tumor tissues, 131I–EGFR–BSA–PCL was 
mostly accumulated in the liver and spleen. The levels of 
131I–EGFR–BSA–PCL and 131I–BSA–PCL in tumor tis-
sues were significantly higher than in the other two groups 
at 24 and 72 h after treatment.
Discussion
Tumor-targeting therapy has overcome the lack of speci-
ficity of traditional therapeutic agents. Liposomes, which 
are spherical vesicles formed by lipid bilayers, have been 
widely investigated as carriers of tumor-targeting therapeu-
tic agents. Some specific ligands have been conjugated to 
nanoparticles that serve as carriers for a therapeutic agent 
and have been used to increase the specific toxicity of 
tumor therapy by specific delivery to target cells, including 
folic acid (Pinhassi et al. 2010), Arg-Gly-Asp peptides (Su 
et al. 2012), vitamins (Chen et al. 2010), aptamers (Neff 
et al. 2011), and antibodies (Mamot et al. 2003). In par-
ticular, immunoliposomes directed against EGFR ligands 
can increase the targeting therapeutic efficacy in vivo and 
may be of important clinical significance as a novel treat-
ment for cancer (Mamot et al. 2005). Previous studies also 
revealed that rapid internalization of the receptor ligand can 
occur upon binding to EGFR (Brand et al. 2011) and that 
PEGylation at the surface of nanoparticles can increase the 
half-life of the nanoparticles in vivo (Gupta and Torchilin 
2007).
The currently available targeting radiotherapies (e.g., 
radionuclide-labeled monoclonal antibodies and peptides) 
have some limitations in targeted radionuclide therapy, such 
as the insufficient delivery of radionuclides to the tumor 
tissue because of the relatively low and heterogeneous 
expression of receptors on tumor cells and the dose-lim-
iting toxicities to normal tissues. Innovative radionuclide 
nanoparticle delivery systems can improve and enhance 
the targeted transport of cytotoxic drugs or radionuclides to 
tumor lesions, maximize the therapeutic index, and mini-
mize the toxicity. Five approaches are generally used for 
labeling or encapsulating radionuclides on nanoparticles: 
labeling nanocarriers by encapsulation during preparation, 
nanocarrier surface labeling after preparation, nanocarrier 
surface labeling of bioconjugates after preparation, incor-
poration into the lipid bilayer after preparation, and after-
loading of the aqueous phase of nanocarriers after prepa-
ration (Ting et al. 2010). In the present research, we used 
the technique of nanocarrier surface labeling after prepara-
tion. The use of active targeting radionuclide nanoparticles 
in internal radiotherapy has been successfully employed 
to image and treat tumor models preclinically. These 
radionuclide nanoparticles include human atherosclerotic 
plaque-specific peptide-1-targeted 111In-labeled liposomes 
(Yang et al. 2012), monoclonal antinuclear autoantibody 
2C5 (mAb 2C5) targeting 111In-immunoliposome for 
lung carcinoma (Elbayoumi et al. 2007), αvβ3-integrin-
targeted 111In perfluorocarbon nanoparticles for targeted 
tumor imaging (Hu et al. 2007), rituximab targeting 111In 
carbon nanotubes for targeted tumor imaging (McDevitt 
et al. 2007), RGD- or VEGF-targeted 64Cu quantum dots 
or iron oxide for PET/NIRF and PET/MRI imaging (Chen 
et al. 2008; Lee et al. 2008), EGFR-targeted 99mTc-chelated 
quantum dots for breast cancer imaging and therapy (Jung 
et al. 2011), RGD-targeted 125I-labeled gold nanoparti-
cles for tumor imaging (Kim et al. 2011), HER2-targeted 
nanoparticles loaded with an 125I-labeled DNA intercalator 
(Fondell et al. 2011), anti-prostate-specific membrane anti-
gen nanoparticles loaded with 225Ac for potential targeted 
Fig. 5  Western blot analysis. The EGFR proteins in MDA-MB-231, 
MDA-MB-453, MDA-MB-468, NCI-H292, NCI-H1975, LS180, and 
A431 cancer cells were 170 kDa. The β-actin protein was used as 
positive control and expressed in all cells at 43 kDa
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Fig. 6  In vitro cytotoxicity of 131I–EGFR–BSA–PCL and 131I–BSA–
PCL. 131I was labeled to EGFR–BSA–PCL and BSA–PCL using the 
chloramine-T method. Cells were treated for 12 h with 131I–EGFR–
BSA–PCL and 131I–BSA–PCL, incubated for 1 day, and counted 
using the MTT assay. MDA-MB-231 (a), MDA-MB-453 (b), MDA-
MB-468 (c), LS180 (d), NCI-H1975 (e), NCI-H292 (f), and A431 
(g). (*p < 0.01, compared with 131I–BSA–PCL; #p > 0.05, compared 
with 131I–BSA–PCL)
628 J Cancer Res Clin Oncol (2016) 142:619–632
1 3
629J Cancer Res Clin Oncol (2016) 142:619–632 
1 3
anti-vascular α-particle therapy (Bandekar et al. 2014), 
76Br-labeled RGD-directed-dendritic nanoprobes for PET 
imaging (Almutairi et al. 2009), and integrin antagonist or 
anti-Flk-1 antibody-coated 90Y-labeled nanoparticles (Li 
et al. 2004).
Radionuclide nanoparticles have other advantages; they 
do not require a homogeneous distribution because emit-
ting radionuclides (such as 131I) can provide remote kill-
ing of cancer cells and they can tolerate imaging during 
treatment. For targeted radionuclide internal radiotherapy 
applications, high energy and low energy between 0.1 and 
2.2 MeV of β-emitters are ideal radioisotopes for the treat-
ment of small-to-large clusters of tumor cells; the maxi-
mum tissue penetration range (1–10 mm) and cross-fire 
effects of β-particles can kill tumor cells in close proximity 
to the neovasculature (Carlsson et al. 2003; Milenic et al. 
2004; Mitra et al. 2006). Several β-emitting radioisotopes, 
such as 131I, 90Y, 186Re, and 177Lu, have been used to treat 
cancer for many years (Ting et al. 2010). Iodine-131 is an 
ideal radionuclide for therapeutic use because of its maxi-
mum β emission of 0.64 MeV with a long physical half-
life of 8 days and a γ emission of 364 keV for imaging 
purposes in the current study. Moreover, 131I radioiodine 
therapy for differentiated thyroid carcinomas has been used 
for numerous years. Given the bystander effect of radia-
tion therapy, radioiodine may kill not only the tumor cells 
with uptake of radionuclide nanoparticles but also adjacent 
tumor cells. Although 131I-labeled anti-EGFR antibody-
targeted radiotherapy has been reported, EGFR-targeted 
131I-labeled nanoparticle radiotherapy in tumor cell lines 
has not yet been reported.
In the present paper, we describe for the first time a 
detailed study showing that EGFR-targeted 131I-labeled 
nanoparticles allowed the evaluation of tumor targeting 
and therapeutic efficacy in vitro. Nanoparticles were con-
structed with anti-EGFR mAb fragments (C225) to deliver 
drugs selectively to tumor cells with EGFR overexpression. 
Using flow cytometry and confocal microscopy analysis, 
the EGFR-targeted nanoparticle EGFR–BSA–PCL showed 
specific binding and internalization in the EGFR-overex-
pressing cell lines MDA-MB-468, MDA-MB-453, and 
MDA-MB-468 (breast cancer); NCI-H292 and NCI-H1975 
(lung cancer); LS180 (colorectal cancer); and A431 (squa-
mous cell carcinoma). Using confocal microscopy, the 
selectivity for tumor cells was confirmed by revealing 
strong and specific binding of EGFR–BSA–PCL to tar-
geted cancer cells. Flow cytometry revealed results consist-
ent with those observed in fluorescent microscopy analyses, 
showing a significant uptake of EGFR–BSA–PCL. Moreo-
ver, the total cellular uptake of EGFR–BSA–PCL in these 
cells was higher than that of non-targeted nanoparticles 
in MDA-MB-231, MDA-MB-453, MDA-MB-468, NCI-
H292, NCI-H1975, LS180, and A431 cell lines (p < 0.05). 
This finding indicates that the targeting ability of EGFR–
BSA–PCL to tumor cells was enhanced via EGFR modi-
fication, resulting in EGFR receptor-mediated endocytosis.
In MTT assays, 131I–EGFR–BSA–PCL was found to 
selectively kill EGFR-overexpressed tumor cells in a dose-
dependent manner after incubation with radionuclide nano-
particles for 4 h. All of the nanoparticles were wiped off 
and the cells were incubated for another 24 h. The value 
of 131I–EGFR–BSA–PCL IC50 in EGFR-overexpressed 
tumor cells was lower than that of 131I–BSA–PCL. The 
cytotoxicity of 131I–EGFR–BSA–PCL was found to be 
dependent on the radiation dose and was higher than that 
with the non-targeted nanoparticle 131I–BSA–PCL. The 
survival rates of 131I–EGFR–BSA–PCL were lower than 
those of 131I–BSA–PCL in all tumor cells. Notably, no tox-
icity was observed when EGFR low expressing cells were 
incubated with the same nanoparticle. The toxic effects of 
EGFR–BSA–PCL and BSA–PCL were very low, as previ-
ously described against the glioma cell line U87 (Liu et al. 
2014).
In the time-dependent cellular uptake experiments of 
131I-labeled nanoparticle nanoparticles, the data showed 
that 131I–EGFR–BSA–PCL exhibited increased 131I accu-
mulation, and the intracellular 131I retention of 131I–EGFR–
BSA–PCL was higher than that of 131I–BSA–PCL because 
the EGFR-targeted nanoparticles demonstrated superior 
cellular binding and enhanced cellular uptake. The cells 
incubated with 131I–BSA–PCL also showed intracellular 
retention of iodine, but the retention was lower in 131I–
BSA–PCL than that in 131I–EGFR–BSA–PCL. PEGylation 
at the surface of nanoparticles has been well documented 
to increase the half-life of the nanoparticles (Gupta and 
Torchilin 2007). Thus, the cell-associated 131I activity after 
24 h was still very high, at almost 79–84 % in all seven 
cell lines. The 131I-labeled nanoparticles showed excellent 
slow-release effects and better-targeted cell killing with 
131I. These nanoparticles may be used in preparations for 
future nude mice studies in vivo.
The high loco-regional retention rate led to good ther-
apeutic results in the radioiodine therapy study in mice. 
In this study, we were able to deliver 74 MBq of radia-
tion for the 131I–EGFR–BSA–PCL and 131I–BSA–PCL 
Fig. 7  Time-dependent uptake and maximal uptake of 131I in differ-
ent cell lines. The maximum 131I uptake for these seven cell lines was 
obtained after 4 h of incubation with 131I–EGFR–BSA–PCL and 131I–
BSA–PCL, but the highest cpm levels were different. The 131I uptake 
of 131I–EGFR–BSA–PCL was higher than that of 131I–BSA–PCL. 
The remaining intracellular retention radioactivity for 131I–EGFR–
BSA–PCL and 131I–BSA–PCL was almost 100 % after 24 h of incu-
bation. The mean values and standard deviations are shown. MDA-
MB-231 (a), MDA-MB-453 (b), MDA-MB-468 (c), LS180 (d), 
NCI-H1975 (e), NCI-H292 (f), and A431 (g). Maximal 131I uptake 
assays in different cell lines (h) (*p < 0.01, compared with 131I–BSA–
PCL)
◂
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nanoparticle groups. The two control groups showed no 
response regarding the unlabeled nanoparticles and showed 
relentless tumor enlargement. The average tumor vol-
umes of the 131I–EGFR–BSA–PCL group was lower than 
those of the 131I–BSA–PCL groups in a mid-stage experi-
ment because EGFR-targeted nanoparticles increased 
tumor cell binding and uptake and led to stronger cell 
killing with 131I. However, the effect of radioiodine ther-
apy became weaker with extended time, so the average 
tumor volumes of the 131I–EGFR–BSA–PCL group were 
similar at the end of the experiment. The data showed 
that 131I therapy could retard tumor growth in a mid-stage 
experiment. The difference between the tumor size of the 
131I–EGFR–BSA–PCL and 131I–BSA–PCL nanoparticle 
groups was most likely due to EGFR-targeted liposomes 
increasing tumor cellular binding and uptake. Although 
intravenous injection of nanoparticles would be simpler and 
better than intratumoral injection in the radioiodine therapy 
study in mice, the data for intravenous injection showed 
that the nanoparticles were mostly retained in the liver and 
Fig. 8  Changes in the tumor volume in NCI-H1972 xenograft nude 
mice and tissue distribution. a The changes in the tumor volume in 
NCI-H1972 xenograft nude mice. The average tumor volumes at 
35 days from the day of nanoparticle injection for the BSA–PCL, 
EGFR–BSA–PCL, 131I–BSA–PCL, and 131I–EGFR–BSA–PCL 
therapy groups. The two control groups showed progressive tumor 
growth; in contrast, the therapy groups showed slow tumor growth 
(n = 5). In comparison, tumors in the EGFR–BSA–PCL and BSA–
PCL nanoparticle control groups showed rapid growth, and the tumor 
volumes were similar at day 15 (p > 0.5). On day 15, the average 
tumor volumes of the 131I–EGFR–BSA–PCL groups were lower than 
131I–BSA–PCL, showing slow growth (*p < 0.01). However, on day 
35, the average tumor volumes of the 131I–EGFR–BSA–PCL and 
131I–BSA–PCL groups were also similar (#p = 0.5). b Tissue dis-
tribution of 131I–EGFR–BSA–PCL, 131I–BSA–PCL, and 131I. 131I–
EGFR–BSA–PCL and 131I–BSA–PCL were markedly absorbed by 
tumor tissues. The tissue distribution assay revealed that 131I–EGFR–
BSA–PCL and 131I–BSA–PCL reached their maximal uptake rate 
(15.96 ± 1.01 %ID/g−1) and (10.79 ± 1.46 %ID/g−1) at 24 h after 
therapy, respectively
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spleen, secondary to the tumor; thus, the treatment effect of 
131I-labeled nanoparticles was poor in vivo. In the in vivo 
radioiodine therapy study, EGFR-targeted 131I-labeled nan-
oparticles had a favorable biological half-life and retarded 
tumor growth to some extent, but the effect of radioiodine 
therapy was decreased with time. This may be because 131I 
did not have enough radiation energy; thus, more power-
ful radionuclides instead of 131I in EGFR-targeted nuclide 
nanoparticles could be used in future research.
In conclusion, EGFR–BSA–PCL exhibited superior cel-
lular binding and enhanced cellular uptake compared with 
the control BSA–PCL. Furthermore, 131I–EGFR–BSA–
PCL achieved a favorable intracellular retention of 131I, 
excellent targeted cell killing, and slow-release effects, and 
it suppressed the cancer cell growth caused by EGFR over-
expression. The radionuclide-targeted anti-EGFR nanopar-
ticle 131I–EGFR–BSA–PCL is a good candidate for tar-
geted drug delivery purposes in EGFR-targeted therapeutic 
approaches for 131I radioiodine treatment for breast cancer, 
lung cancer, colorectal cancer, and squamous cell carci-
noma cell lines.
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